
FDA Publishes Guidance on Drug Development for Male Breast Cancer
The agency provides recommendations for development and labeling of drugs to treat male patients with breast cancer.
FDA released
The guidance recommends that both males and females should be included in eligibility criteria for clinical trials. “FDA does not intend to consider low expected accrual rates of male patients with breast cancer to be a sufficient scientific rationale for excluding them from a clinical trial,” the guidance states. In addition, the guidance states, “sponsors should conduct nonclinical general toxicology studies in male and female animals” when males are included in clinical trials for breast cancer treatments.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.